Economic burden of renal cell carcinoma among older a

Urologic Oncology: Seminars and Original Investigations 37, 356.e19-356.e28 DOI: 10.1016/j.urolonc.2019.01.016

Citation Report

#	Article	IF	CITATIONS
1	Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2020, 10, 592243.	1.3	8
2	Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer, 2021, 5, 47-62.	0.2	2
3	Race/ethnicity and advanced stage of renal cell carcinoma in adults: results from surveillance, epidemiology, and end results program 2007–2015. European Journal of Cancer Prevention, 2022, 31, 172-177.	0.6	1
6	The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy. BMC Cancer, 2022, 22, 491.	1.1	6
7	Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: A qualitative study. Asia-Pacific Journal of Oncology Nursing, 2022, 9, 100115.	0.7	2
8	Cost-effectiveness of minimally invasive partial nephrectomy and percutaneous cryoablation for cT1a renal cell carcinoma. European Radiology, 2023, 33, 1801-1811.	2.3	2
9	The health-related quality of life of lung cancer patients with EGFR-TKI-related skin adverse drug reactions and its relationship with coping style and self-management. Supportive Care in Cancer, 2022, 30, 9889-9899.	1.0	2
10	Home-based multidisciplinary interventions on skin adverse reactions in EGFR-TKI-treated patients with lung cancer: a protocol for a randomised controlled trial. BMJ Open, 2022, 12, e063921.	0.8	0
11	Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States. Clinical Genitourinary Cancer, 2023, 21, 238-247.	0.9	2